A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness

Maturitas

Volumn 53, Issue 4, 2006, Pages 413-423

  Christodoulakos, George E ^a   Botsis, Dimitrios S ^a   Lambrinoudaki, Irene V ^a   Papagianni, Vasiliki D ^a   Panoulis, Constantinos P ^a   Creatsa, Maria G ^a   Alexandrou, Andreas P ^a   Augoulea, Areti D ^a   Dendrinos, Spyros G ^a   Creatsas, George C ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Conjugated equine estrogen; Endometrial thickness; Estradiol; Progestin; Raloxifene; Tibolone; Vaginal bleeding

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ACETATE; RALOXIFENE; TIBOLONE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENDOMETRIUM; FEMALE; HORMONAL THERAPY; HUMAN; HYSTEROSCOPY; MAJOR CLINICAL STUDY; MENOPAUSE; TRANSVAGINAL ECHOGRAPHY; VAGINA BLEEDING;

AGED; ENDOMETRIUM; ESTROGEN RECEPTOR MODULATORS; ESTROGEN REPLACEMENT THERAPY; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; METRORRHAGIA; MIDDLE AGED; NORPREGNENES; PATIENT DROPOUTS; POSTMENOPAUSE; PROSPECTIVE STUDIES; RALOXIFENE; STATISTICS;

EQUIDAE;

EID: 33644628661     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2005.07.003     Document Type: Article

References (63)

1. W.H. Utian, D. Shoupe, G. Bachmann, J.V. Pinkerton, and J.H. Pickar Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate Fertil Steril 75 2001 1065 1079
2. J.H. Pickar, I.T. Yeh, J.E. Wheeler, M.F. Cunnane, and L. Speroff Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year sub-study results Fertil Steril 80 2003 1234 1240
3. M. Wells, D.W. Sturdee, and D.H. Barlow Effect on endometrium of long term treatment with continuous combined oestrogen-progestogen replacement therapy: follow up study BMJ 325 7358 2002 239
4. G.L. Anderson, H.L. Judd, and A.M. Kaunitz Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative Randomized Trial JAMA 290 2003 1739 1748
5. V. Beral, D. Bull, G. Reeves Million Women Study Collaborators Endometrial cancer and hormone-replacement therapy in the Million Women Study Lancet 365 2005 1543 1551
6. D.W. Sturdee, L.G. Ulrich, and D.H. Barlow The endometrial response to sequential and continuous combined oestrogen-progestogen replacement therapy BJOG 107 2000 1392 1400
7. M.C. Pike, R.K. Peters, and W. Cozen Estrogen-progestin replacement therapy and endometrial cancer J Natl Cancer Inst 89 1997 1110 1116
8. A. Di Spiezio Sardo, and S. Radhakrishnan Endometrial carcinoma on continuous combined HRT: case report and literature review Maturitas 48 2004 171 175
9. D.F. Archer, J.H. Pickar, F. Bottiglioni Menopause Study Group Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate Obstet Gynecol 83 1994 686 692
10. S. Mirkin, F. Navarro, and D.F. Archer Hormone therapy and endometrial angiogenesis Climacteric 6 2003 273 277
11. J.H. Pickar, D.F. Archer Menopause Study Group Is bleeding a predictor of endometrial hyperplasia in postmenopausal women receiving hormone replacement therapy? Am J Obstet Gynecol 177 1997 1178 1183
12. U. Omodei, E. Ferrazzi, and F. Ramazzotto Endometrial evaluation with transvaginal ultrasound during hormone therapy: a prospective multicenter study Fertil Steril 81 2004 1632 1637
13. E. Ferrazzi, and F.P. Leone Investigating abnormal bleeding on HRT or tamoxifen: the role of ultrasonography Best Pract Res Clin Obstet Gynaecol 18 2004 145 156
14. The Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women JAMA 288 2002 321 333
15. M. De Gooyer, G. Deckers, W. Schoonen, H. Verheul, and H. Kloosterboer Receptor profiling and endocrine interactions of tibolone Steroids 68 2003 21 30
16. K. Modelska, and S. Cummings Tibolone for postmenopausal women: systematic review of randomized trials J Clin Endocrinol Metab 87 2002 16 23
17. E. Lundstrom, A. Christow, and W. Kersemaekers Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density Am J Obstet Gynecol 186 2002 717 722
18. J. van de Ven, G.H. Donker, M. Sprong, M.A. Blankenstein, and J.H. Thijssen Effect of tibolone (Org OD14) and its metabolites on aromatase and estrone sulfatase activity in human breast adipose stromal cells and in MCF-7 and T47D breast cancer cells J Steroid Biochem Mol Biol 81 2002 237 247
19. M. Doren, A. Rubig, H.J. Coelingh Bennink, and W. Holzgreve Impact on uterine bleeding and endometrial thickness: tibolone compared with continuous combined estradiol and norethisterone acetate replacement therapy Menopause 6 1999 299 306
20. W. Volker, H.J. Coelingh Bennink, and F.A. Helmond Effects of tibolone on the endometrium Climacteric 4 2001 203 208
21. P.D. Delmas, N.H. Bjarnason, and B.H. Mitlak Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women N Engl J Med 337 1997 1641 1647
22. E.E. Jolly, N.H. Bjarnason, and P. Neven Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years Menopause 10 2003 337 344
23. B.W. Walsh, S. Paul, and R.A. Wild The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial J Clin Endocrinol Metab 85 2000 214 218
24. C.C. Johnston Jr., N.H. Bjarnason, and F.J. Cohen Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials Arch Intern Med 160 2000 3444 3450
25. G. Christodoulakos, I. Lambrinoudaki, C. Panoulis, D. Rizos, J. Coutoukos, and G. Creatsas Effect of raloxifene, estrogen, and hormone replacement therapy on serum homocysteine levels in postmenopausal women Fertil Steril 79 2003 455 456
26. S. Martino, J.A. Cauley, and E. Barrett-Connor CORE Investigators Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene J Natl Cancer Inst 96 2004 1751 1761
27. J.A. Cauley, L. Norton, and M.E. Lippman Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation Breast Cancer Res Treat 65 2001 125 134
28. F.J. Cohen, S. Watts, A. Shah, R. Akers, and L. Plouffe Jr. Uterine effects of 3-year raloxifene therapy in postmenopausal women younger than age 60 Obstet Gynecol 95 2000 104 110
29. E. Barrett-Connor, D. Grady, and A. Sashegyi MORE Investigators (Multiple Outcomes of Raloxifene Evaluation). Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial JAMA 287 2002 847 857
30. J.E. Heikkinen, R.T. Vaheri, S.M. Ahomaki, P.M. Kainulainen, A.T. Viitanen, and U.M. Timonen Optimizing continuous-combined hormone replacement therapy for postmenopausal women: a comparison of six different treatment regimens Am J Obstet Gynecol 182 2000 560 567
31. D.F. Archer, M. Dorin, V. Lewis, D.L. Schneider, and J.H. Pickar Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding Fertil Steril 75 2001 1080 1087
32. J.A. Simon, J.P. Symons Femhrt Study Investigators Unscheduled bleeding during initiation of continuous combined hormone replacement therapy: a direct comparison of two combinations of norethindrone acetate and ethinyl estradiol to medroxyprogesterone acetate and conjugated equine estrogens Menopause 8 2001 321 327
33. M.C. Wender, M.I. Edelweiss, L.S. Campos, J.A. de Castro, and P.M. Spritzer Endometrial assessment in women using tibolone or placebo: 1-year randomized trial and 2-year observational study Menopause 11 2004 423 429
34. P. Neven, D. Quail, and M. Levrier Uterine effects of estrogen plus progestin therapy and raloxifene: adjudicated results from the EURALOX study Obstet Gynecol 103 2004 881 891
35. J. Rymer, I. Fogelman, and M.G. Chapman The incidence of vaginal bleeding with tibolone treatment Br J Obstet Gynaecol 101 1994 53 56
36. HJ.T. Bennink Are all estrogens the same? Maturitas 47 2004 269 275
37. L.A. Mattsson, S.O. Skouby, J. Heikkinen, R. Vaheri, J. Maenpaa, and U. Timonen A low-dose start in hormone replacement therapy provides a beneficial bleeding profile and few side-effects: randomized comparison with a conventional-dose regimen Climacteric 7 2004 59 69
38. M. Rees, S. Hague, M.K. Oehler, and R. Bicknell Regulation of endometrial angiogenesis Climacteric 2 1999 52 58
39. D.F. Archer, F.J. Navarro, S. Leslie, and S. Mirkin Effects of levonorgestrel, medroxyprogesterone acetate, norethindrone, and 17beta-estradiol on vascular endothelial growth factor isomers 121 and 165 in Ishikawa cells Fertil Steril 81 2004 165 170
40. N. Seki, J. Kodama, I. Hashimoto, A. Hongo, M. Yoshinouchi, and T. Kudo Thrombospondin-1 and -2 messenger RNA expression in normal and neoplastic endometrial tissues: correlation with angiogenesis and prognosis Int J Oncol 19 2001 305 310
41. C. Legault, S. Slone, and H. Judd Bleeding patterns over 3 years in postmenopausal women taking placebo or 4 different combinations of oestrogens and progestins. The PEPI Trial Menopause 6 1999 325 326
42. G. Christodoulacos, C. Panoulis, D. Botsis, D. Rizos, D. Kassanos, and G. Creatsas Transvaginal sonographic monitoring of the uterine effects of raloxifene and a continuous combined replacement therapy in postmenopausal women Maturitas 42 2002 77 84
43. P. Fugere, W.H. Scheele, A. Shah, T.R. Strack, M.D. Glant, and E. Jolly Uterine effects of raloxifene in comparison with continuous-combined hormone replacement therapy in postmenopausal women Am J Obstet Gynecol 182 2000 568 574
44. P. Neven, T. Lunde, P. Benedetti-Panici Eurolox 1 Study Group A multicentre randomised trial to compare uterine safety of raloxifene with a continuous combined hormone replacement therapy containing oestradiol and norethisterone acetate BJOG 110 2003 157 167
45. T. Perez-Medina, J. Bajo-Arenas, and J. Haya Tibolone and risk of endometrial polyps: a prospective, comparative study with hormone therapy Menopause 10 2003 534 537
46. J. Ginsburg, G. Prelevic, D. Butler, and S. Okolo Clinical experience with tibolone (Livial) over 8 years Maturitas 21 1995 71 76
47. M. Habiba, J. Ramsay, A. Akkad, D.M. Hart, and F. al-Azzawi Immunohistochemical and hysteroscopic assessment of postmenopausal women with uterine bleeding whilst taking Tibolone Eur J Obstet Gynecol Reprod Biol 66 1996 45 49
48. D. Bruce, J. Robinson, and J. Rymer Long-term effects of tibolone on the endometrium as assessed by bleeding episodes, transvaginal scan and endometrial biopsy Climacteric 7 2004 261 266
49. J.H. Meuwissen, M.A. Wiegerinck, and M.J. Haverkorn Regression of endometrial thickness in combination with reduced withdrawal bleeding as a progestational effect of tibolone in postmenopausal women on oestrogen replacement therapy Maturitas 21 1995 121 125
50. R. Trevoux, P. Dieulangard, and A. Blum Efficacy and safety of Org OD 14 in the treatment of climacteric complaints Maturitas 5 1983 89 96
51. D. De Aloysio, A.G. Fabiani, M. Mauloni, and F. Bottiglioni Use of Org OD 14 for the treatment of climacteric complaints Maturitas Suppl. 1 1987 49 65
52. S.R. Goldstein, W.H. Scheele, S.K. Rajagopalan, J.L. Wilkie, B.W. Walsh, and A.K. Parsons A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium Obstet Gynecol 95 2000 95 103
53. G.D. de Azevedo, M.F. do Prado, and R.A. Ferriani Raloxifene therapy does not affect uterine blood flow in postmenopausal women: a transvaginal Doppler study Maturitas 47 2004 195 200
54. G.C. Davies, W.J. Huster, and W. Shen Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women Menopause 6 1999 188 195
55. S.R. Cummings, S. Eckert, and K.A. Krueger The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation JAMA 281 1999 2189 2197
56. W. Hanggi, N. Bersinger, H.J. Altermatt, and M.H. Birkhauser Comparison of transvaginal ultrasonography and endometrial biopsy in endometrial surveillance in postmenopausal HRT users Maturitas 27 1997 133 143
57. E. Chalas, J.P. Costantino, and D.L. Wickerham Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial Am J Obstet Gynecol 192 4 2005 1230 1237
58. R. Erkkola, U. Kumento, S. Lehmuskoski, L. Mattila, and M. Mustonen No increased risk of endometrial hyperplasia with fixed long-cycle oestrogen-progestogen therapy after five years J Br Menopause Soc 10 2004 9 13
59. L. Warming, P. Ravn, T. Nielsen, and C. Christiansen Safety and efficacy of drospirenone used in a continuous combination with 17beta-estradiol for prevention of postmenopausal osteoporosis Climacteric 7 2004 103 111
60. G. Kurtay, B. Berker, and C. Demirel Transvaginal ultrasonographic assessment of the endometrium in asymptomatic, postmenopausal women using different HRT regimens containing tibolone or estrogen J Reprod Med 49 2004 893 898
61. R. Yazigi, S. Sahid, L. Contreras, and T. Rodriguez Carcinoma of the endometrium in patients treated with tibolone Gynecol Oncol 93 2004 568 570
62. P. von Dadelszen, M.D. Gillmer, and M.D. Gray Endometrial hyperplasia and adenocarcinoma during tibolone (Livial) therapy Br J Obstet Gynaecol 101 1994 158 161
63. C.S. de Vries, S.E. Bromley, H. Thomas, and R.D. Farmer Tibolone and endometrial cancer: a cohort and nested case-control study in the UK Drug Saf 28 2005 241 249